NRX Pharmaceuticals Inc (NRXP) Stock Analysis
Verdict: AVOID
FDA ketamine ANDA approval provides commercial optionality, but severe cash burn and recurring equity dilution keep risk profile speculative.
Investment score: 31/100
Analysis as of
Is NRX Pharmaceuticals Inc stock worth reviewing? The TradeMates thesis
TradeMates views NRx Pharmaceuticals as speculative following recent FDA ANDA approval for preservative-free ketamine, as ongoing operational losses and persistent dilution risks outweigh regulatory milestones.
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 25/100 (weight 15%)
- Technical Momentum: 45/100 (weight 15%)
- Earnings Quality: 20/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 40/100 (weight 10%)
- Risk-Adjusted Return: 30/100 (weight 15%)
NRX Pharmaceuticals Inc opportunities and risks
What speaks for NRXP
- FDA ANDA approval for preservative-free ketamine on October 30, 2026.
What speaks against NRXP
- Severe operational cash burn and imminent dilution risk.
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| NRXP | n/a | 31.8x | n/a | 32.7% | -691.8% | -19.2% |
| JUSH.CN | n/a | 0.3x | 5.1x | 42.3% | -19.8% | 6.2% |
| DERM | n/a | 2.0x | 71.3x | 62.2% | -9.0% | -5.6% |
| GRIN.CN | n/a | 2.2x | 48.2x | 45.0% | -6.4% | -1.7% |
| LENZ | n/a | 8.8x | n/a | 80.2% | -1135.0% | -117.5% |
| NMRA | n/a | 0.0x | 0.0x | 0.0% | 0.0% | -169.7% |
| Peer median | n/a | 2.0x | 5.1x | 45.0% | -9.0% | -5.6% |
Frequently asked questions about NRX Pharmaceuticals Inc (NRXP)
Is NRXP stock a good investment?
The TradeMates model rates NRX Pharmaceuticals Inc as AVOID with an investment score of 31/100. TradeMates views NRx Pharmaceuticals as speculative following recent FDA ANDA approval for preservative-free ketamine, as ongoing operational losses and persistent dilution risks outweigh regulatory milestones. This is algorithmic model output, not personal investment advice.
Is NRXP stock a buy?
The TradeMates model verdict for NRXP is AVOID with an investment score of 31/100. Treat this as a model signal to review, not a personal buy recommendation.